TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients - Wikidata - wikimedia - TriplyDB

TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients

TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients

http://www.wikidata.org/entity/Q34398397

about

A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers Wilms tumor 1 mutations in the pathogenesis of acute myeloid leukemia Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia Defining and Treating Older Adults with Acute Myeloid Leukemia Who Are Ineligible for Intensive Therapies Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma.TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation.Role of TET enzymes in DNA methylation, development, and cancer Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia Myelodysplastic Syndromes Diagnosis: What Is the Role of Molecular Testing?Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes Established and emerging targeted therapies in the myelodysplastic syndromes.[Myelodysplastic syndromes].Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes.Molecular Testing in Patients with Suspected Myelodysplastic Syndromes.A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia.Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome.The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia The curious origins of angioimmunoblastic T-cell lymphoma Potential relationship between inadequate response to DNA damage and development of myelodysplastic syndrome.Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes.Recent advances in myelodysplastic syndromes: Molecular pathogenesis and its implications for targeted therapies.Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia.Transfer RNA detection by small RNA deep sequencing and disease association with myelodysplastic syndromes.Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia.Prognostic Impact of IPSS-R and Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic Syndrome Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides.High expression of the human equilibrative nucleoside transporter 1 gene predicts a good response to decitabine in patients with myelodysplastic syndrome.The Impact of DNA Methylation in Hematopoietic Malignancies.Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents.Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion Mutations in histone modulators are associated with prolonged survival during azacitidine therapy.Peripheral blood cell-free DNA is an alternative tumor DNA source reflecting disease status in myelodysplastic syndromes.TET2 mutations were predictive of inferior prognosis in the presence of ASXL1 mutations in patients with chronic myelomonocytic leukemia.Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome.

P2860

Q26743743-35DFB7C6-0C91-4B5D-AA71-5E980D1C2AA6 Q26744111-A52364D8-43FB-4D23-811D-DD9E2897CB1F Q26768600-5E97D07B-1B1A-4F01-B300-34396554316C Q26772235-D255E1EB-4C71-49AC-8844-DC4B42EBD2F4 Q26796240-E794BD16-7C09-48A6-9191-8CB3E7904269 Q26801573-03141883-69C4-4539-BA9B-57FB4FD67261 Q27853198-07221C2E-AE15-4980-94D6-43B93944B53B Q27853319-85443081-3AA8-4B14-8ADA-7A465D3AF157 Q28068541-78FF4A47-4EA4-43EC-B7EA-ED8DBE488E27 Q28084813-304B305C-96D2-4016-81EA-3386ED718C8E Q28387115-3C624E74-3D1E-40B9-B483-6A74B9703001 Q28392451-F57CE7D4-62E4-4EDE-BC03-38EC77136241 Q30245476-1E9EFB83-3587-4FE0-95DB-A6709D15CA13 Q33420574-59643FA6-D33C-4FD0-8C50-91A13A78F276 Q33427165-A771A57D-7B0E-47AB-8D89-BD680B5F3EDE Q33435980-BCD198E9-F037-4FA5-999A-F5FE0854E7D1 Q33442672-D92172C2-26E7-4DE9-907B-0F5E61BB3B79 Q33600822-447805CE-85FD-428A-84F6-AE79C1D3F048 Q33796552-0F9E3FB9-706A-4D91-A964-02226C3A84A6 Q33877993-5C46D8D7-CA41-4DFA-A5A4-8639335CE427 Q35016534-EB877652-0D26-4749-BBAF-59C78B0295FC Q35183982-571A4D76-FBED-4C71-A55B-B884FE6CB9F3 Q35538419-3380D50B-3FE2-48B6-96FF-DD21A9F51EAC Q35546759-C7CAD67E-4702-46AE-8952-67CC23001A99 Q35785942-1E6CDBC4-E965-4638-BD10-7C14A13556C9 Q36179524-B8B836DC-F990-4FB8-9686-8A5E4DBED001 Q36185741-3D817D94-4CB9-48E9-B940-4F65B123DEE4 Q36548070-05749240-0BFB-4DDE-ACA2-5225522B41D1 Q36642726-5DC327FF-897F-423A-9E02-D21C0B041AE6 Q36654373-C65897A6-8BF9-43EF-8828-3149C34F8FB0 Q36724810-A9BBB578-FFA4-4463-BC8F-AFC47760B038 Q37046564-593367DE-1189-41ED-870F-D734380D9C20 Q37074311-3B1B9720-8083-4FB6-A54B-ACEB8129F3A2 Q37075929-3EE3F700-1F32-4A4E-BFE5-9EAB96D7E8A9 Q37225482-9932B19D-97A4-4E03-87F0-D7F921B73299 Q37252302-C8F2541C-3F0A-4BE8-AEF9-5262C333ED2E Q37345073-56ADE7DB-F4CC-4AF5-B47D-5CCBC0836236 Q37349392-5A9D2C0B-DEBD-43E6-91C2-158A8541A83B Q37566878-16EA3003-61DE-428C-BD3A-317F8471EE2D Q37688233-D986BE82-412D-4654-9962-9FF82ECA363E

P2860

TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients

http://www.wikidata.org/entity/Q34398397

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

TET2 mutations predict respons ...... lodysplastic syndrome patients

@ast

TET2 mutations predict respons ...... lodysplastic syndrome patients

@en

TET2 mutations predict respons ...... lodysplastic syndrome patients

@nl

type

label

TET2 mutations predict respons ...... lodysplastic syndrome patients

@ast

TET2 mutations predict respons ...... lodysplastic syndrome patients

@en

TET2 mutations predict respons ...... lodysplastic syndrome patients

@nl

prefLabel

TET2 mutations predict respons ...... lodysplastic syndrome patients

@ast

TET2 mutations predict respons ...... lodysplastic syndrome patients

@en

TET2 mutations predict respons ...... lodysplastic syndrome patients

@nl

P1433

Q34398397-F53BF5AA-4D65-4ECC-B2F6-B9EF5757F80C

P1476

Q34398397-116891C7-4EA0-4DAA-931B-AFC5E51517EE

P2093

Q34398397-23577947-8D74-45D0-8E8A-D7631F92C9CB

Q34398397-2895CA0A-4CC4-42FF-8627-524DBF481A97

Q34398397-2F4ECCBE-1606-4744-899E-CE249953F828

Q34398397-30471298-F4E6-4BBF-81E0-430BBC29DB07

Q34398397-49784BD6-A932-4B84-AAF1-FCEE759D68C7

Q34398397-4C249A3E-AC32-4B00-A168-6FB915A842E9

Q34398397-683AEA8E-AC0A-41D3-B364-1A8E04B30AEF

Q34398397-9136F4AB-D69D-43FB-BEB1-F3259E97E8B1

Q34398397-AA64D8DE-ADAA-4208-8BBF-FB1A10D74759

Q34398397-B09DFCDD-A47B-4FDA-AC23-A67D1251DA8D

P2860

Q34398397-0C132DBD-26DD-4E8C-A34A-86DB482619DD

Q34398397-13E0422F-BD4C-4DD6-BA61-7622C205BEFD

Q34398397-14C78738-6814-4E35-93EE-D1A908271F63

Q34398397-1DDF9B50-6955-490A-8A57-6F4851AFFCE4

Q34398397-1E02AB84-CF29-4E03-AA72-56C03B76C385

Q34398397-1F1CE0F0-9A5B-4B40-928D-C497A402B872

Q34398397-20D20FAA-431C-4CC1-8078-6314A0A74AF8

Q34398397-292230FB-BEBE-4DC8-900E-522510BA4AE0

Q34398397-41517787-8EC8-484E-BD0A-57AA9840D8B2

Q34398397-41B8C7E4-9B50-48B5-B1F5-01B6CB62BD89

P304

Q34398397-9BAC8ACA-976A-4DC2-9EF0-FD5E7C8C3D31

P31

Q34398397-76AE1034-F66D-4519-A19D-2AEC6ECEED2D

P356

Q34398397-ADD5A0A4-6572-407F-952D-CDB2765E6EB2

P407

Q34398397-90DBDCDD-B4D7-4022-B0FE-69CD7029B394

P433

Q34398397-17E84148-2338-4C64-9B77-14D26DDFAE8D

P478

Q34398397-145B72BA-2D77-4721-BC69-73148E0EAC74

P50

Q34398397-7EC9A262-AEA9-4C3D-A2DA-BC47CBD1B52E

Q34398397-A3D38162-F9C6-4147-B92C-08D89C736F53

Q34398397-EE3C2854-EBE6-4997-8A6E-6D96E0E84BD7

P577

Q34398397-AC9D0644-7CA6-4DEA-B163-EFE331C1DC20

P5875

Q34398397-0F11DE36-A913-44E0-B518-3D1C9139FF70

P698

Q34398397-8CD3C550-8640-41A5-846A-8E0208885EF1

P932

Q34398397-A20C4C61-0725-4A3E-8603-8210A880DDE3

P356

BLOOD-2014-06-582809

P1433

P1476

TET2 mutations predict respons ...... lodysplastic syndrome patients

@en

P2093

Albert Pérez-Ladaga

http://www.w3.org/2001/XMLSchema#string

Allegra Lord

http://www.w3.org/2001/XMLSchema#string

Benjamin L Ebert

http://www.w3.org/2001/XMLSchema#string

Bennett Caughey

http://www.w3.org/2001/XMLSchema#string

David P Steensma

http://www.w3.org/2001/XMLSchema#string

Donna Neuberg

http://www.w3.org/2001/XMLSchema#string

Hui Wang

http://www.w3.org/2001/XMLSchema#string

Jacques Zaneveld

http://www.w3.org/2001/XMLSchema#string

Kristen Stevenson

http://www.w3.org/2001/XMLSchema#string

Michal Bar-Natan

http://www.w3.org/2001/XMLSchema#string

P2860

ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression

Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.

Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation

Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies

Fast and accurate long-read alignment with Burrows-Wheeler transform

A framework for variation discovery and genotyping using next-generation DNA sequencing data

Frequent pathway mutations of splicing machinery in myelodysplasia

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

P304

2705-2712

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2014-06-582809

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

124

http://www.w3.org/2001/XMLSchema#string

P50

Hagop Kantarjian

Guillermo Garcia-Manero

P577

2014-09-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

265692492

http://www.w3.org/2001/XMLSchema#string

P698

25224413

http://www.w3.org/2001/XMLSchema#string

P932

4208285

http://www.w3.org/2001/XMLSchema#string